Navigation Links
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
Date:4/4/2013

mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for RA with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.  For more information, visit www.rigel.com

About AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

This press release contains "forward-looking" statements, including, without limitation, statements related to the further development of, and the therapeutic and commercial potential of, fostamatinib, partnered with AstraZeneca, the results of the ongoing OSKIRA-2 and OSKIRA-3 Phase 3 studies and the timing of completion of those studies, and the timing for potential regulatory filings and publications of clinical data. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "may," "expect," and similar expressions are intended to identify these forward-looking statements.  These forward-looking statements are based on Rigel's current expectations and inheren
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
3. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
4. AstraZeneca Acquires Neuroscience Assets From Link Medicine
5. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
6. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
7. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
8. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
9. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
10. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
11. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Sorrento ... that it has entered into an exclusive licensing agreement ... or biobetter antibodies from Mabtech Limited, a holding company ... China . Under the ... these 4 monoclonal antibodies (mAbs) for the North American, ...
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... MOUNT PROSPECT, Ill. , July 31, 2015 ... of Pharmacy ® (NABP ® ) issued ... charged with ensuring that action is taken against ... the Internet Drug Outlet Identification Program ... 2015 , thousands of websites ...
Breaking Medicine Technology:Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3
(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and amputation , AUGUST 3, 2015 – Since winning a South by Southwest® ... Not Impossible – an organization whose mission is to develop technology for the ...
(Date:8/3/2015)... ... 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and ... Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker ... the Company’s presentation may be accessed via the investor relations section of the Company’s ...
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. Baldwin, ... Room – Gilbert, opening in August. The new facility is licensed under ... Valley. , “Dr. Baldwin is an excellent leader and will ensure our new ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... highlighted, MCLEAN, Va., Sept. 14 As part of ... the USA",25- week charity program that highlights a different charity ... 30th and continued each Friday as USA TODAY,thanked America for ... generosity. USA TODAY has selected 25 charities and has celebrated,the ...
... scientists recently discovered an association between being overweightand a ... This discovery was published in the Sept. 14 issue ... group led by Dr. Corazziari from the University La ... in the field of gastroenterology for a long time ...
... risk of genetic condition that can lead to early ... simple blood test early in life could identify children ... cholesterol levels and greatly increases the risk of early ... Drug treatment could eventually be started to reduce that ...
... of your level of,expertise, you will have a lot to ... Do you know: The essential DNA for quality ... How to exploit process and quality for competitive advantage? ... How to achieve product innovation excellence? The benefits ...
... Inc. (Nasdaq: MTMD ) announced today that ... under the Hart-Scott-Rodino Antitrust,Improvements Act of 1976, as ... Microtek Medical Holdings, Inc. The Boards of,Directors for ... expected to close during the fourth quarter of ...
... With In-depth Information on,Injured Players, ALEXANDRIA, Va., ... as the real-life games, enthusiasts can now look,to ... for a,better understanding of the injuries plaguing their ... Bell, PT, MS, OCS,CSCS, has joined ESPN.com as ...
Cached Medicine News:Health News:USA TODAY Concludes 'Spirit of the USA' Charity Program as Part of Newspaper's 25th Anniversary Celebration 2Health News:USA TODAY Concludes 'Spirit of the USA' Charity Program as Part of Newspaper's 25th Anniversary Celebration 3Health News:Screening Proposed for Childhood Cholesterol Levels 2Health News:Screening Proposed for Childhood Cholesterol Levels 3Health News:Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right 2Health News:Microtek Medical Receives Early Termination of Hart-Scott-Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab 2Health News:Microtek Medical Receives Early Termination of Hart-Scott-Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab 3Health News:Physical Therapist Provides Injury Analysis for Fantasy Football 2
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... Diagnostics Task Targeted Automation VS ... automation of pre- and post-analytical ... sorting / archiving of primary ... code labeled secondary tubes. Fully ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... and gain efficiency in the lab ... (LAS), the high-throughput aliquotting solution with ... Olympus OLA2500 LAS is an advanced ... to high-volume laboratories. As a front-end ...
Medicine Products: